University of Tennessee West Cancer Center | Strategic Alliance Partners

March 02, 2023

Gregory Vidal, MD, PhD, discusses racial disparities in the treatment of patients with breast cancer.

July 07, 2022

Gregory Vidal, MD, PhD, discusses the impact of the phase 3 KATHERINE trial in HER2-positive breast cancer.

July 06, 2022

Gregory Vidal, MD, PhD, including the evolution of treatment options for HER2-low breast cancer, emerging antibody-drug conjugates in triple-negative disease, and the viability of HER3 as an emerging target in breast cancer

December 22, 2021

Lee S. Schwartzberg, MD, discusses the culmination of research with androgen-targeted agents in metastatic androgen receptor–positive, estrogen receptor–positive breast cancer and ongoing research that could lead to a paradigm shift in the second-line setting.

December 20, 2021

Dr. Schwartzberg discusses the rationale to evaluate enobosarm in androgen receptor-positive, estrogen recepetor-positive advanced breast cancer, phase 2 data with the agent, and expectations for the ongoing phase 3 ARTEST trial in this population.

June 29, 2021

Results from a partnership to address disparities and enhance the quality of breast cancer care atMemphis-based West Cancer Center & Research Institute were announced today.

June 23, 2021

Genentech, a member of the Roche Group, today announced the creation of the Advancing Inclusive Research® Site Alliance.

May 14, 2021

Axel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.

May 05, 2021

Axel Grothey, MD, discusses the potential role of circulating tumor DNA testing in screening patients for early-stage colorectal cancer.

April 05, 2021

Axel Grothey, MD, discusses the potential applications for ctDNA in CRC and shed light on the updated analysis from the pivotal IMbrave150 trial in advanced hepatocellular carcinoma.

March 31, 2021

Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer.

March 24, 2021

David C. Portnoy, MD, FACP, discusses ongoing studies examining immunotherapy and what is needed to move the needle forward in SCLC.

March 08, 2021

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

March 03, 2021

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

February 25, 2021

Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.

February 16, 2021

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

February 15, 2021

Fam-trastuzumab deruxtecan-nxki is under study alone and in combination for the treatment of patients with HER2-overexpressing locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in the ongoing phase 1b/2 DESTINY-Gastric03 trial.

February 11, 2021

Axel Grothey, MD, discusses potential combination strategies with fam-trastuzumab deruxtecan-nxki in gastrointestinal malignancies.

February 10, 2021

Axel Grothey, MD, highlights recent advancements in CRC treatment, including innovative combinations and emerging agents that are generating excitement in the field.

January 04, 2021

Axel Grothey, MD, discusses the results of the phase 2 ANCHOR-CRC trial in patients with BRAF-mutant metastatic colorectal cancer.